drug
aceclidine
Marketedupdated 6mo agoby $LENZ LENZ Therapeutics, Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying aceclidine
- phase3Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
- phase3Phase 3 Safety Study for the Treatment of Presbyopia Subjects
- phase1Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia
- phase1Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 31, 2030
~3.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Mar 15, 2044method-of-use (U-3741)US 12414942
- Oct 8, 2039method-of-use (U-3741)US 12128036
- Oct 8, 2039method-of-use (U-3741)US 12533347
- Mar 24, 2034formulationUS 10052313
- Mar 24, 2034method-of-use (U-3741)US 11179328
- Mar 24, 2034formulationUS 9844537
FDA exclusivities (1)
- Jul 31, 2030NCENew Chemical Entity (5y)3.7y
News(1)
- Biopharma layoffs rise YOY in October but sharply trend down for 2026October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025…biospace · 5d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that